In May, The Memphis Bioworks Foundation will launch TriMetis, a for-profit research company that will be the first of its kind in the region.
The 26,000-square-foot TriMetis facility will be the third new construction project at the UT-Baptist Research Park.
Phil Cestaro, TriMetis president, says the company will operate the Memphis Specialized Laboratory, a facility designed to help medical device, pharmaceutical, industrial, biotech and academic institutions conduct research that will meet the quality levels and oversight required by the U.S. Food and Drug Administration.
Cestaro estimates Memphis companies are exporting $3 million to $5 million annually because the city does not have a facility for pre-clinical studies that meets the requirements of the FDA. The lab will be the only pre-clinical research facility in the state of Tennessee.
Pre-clinical research is one of the earliest phases of the FDA-approval process before pharmaceuticals or medical devices can move forward in the development pipeline.
UT-Baptist Research Park
The 26,000-square-foot facility is the third new construction project on the UT-Baptist Research Park, representing more than $120 million in investment.
Companies and organizations can pay TriMetis directly to conduct research, or they can also lease space from TriMetis and conduct their own research trials.
The lab has strict security to protect intellectual property and to meet the FDA’s rules and regulations. Because of those rules and to protect intellectual property, TriMetis won’t always be able to reveal their clients and the type of research projects that will be conducted at the facility.
Cestaro says the lab will help lure economic investment from both Memphis companies, and those elsewhere in the U.S.